- Author
-
Z. Zazuli
- Title
- Optimizing safety of cisplatin treatment
- Subtitle
- Utilizing pharmacogenomics to prevent nephrotoxicity
- Supervisors
-
A.H. Maitland-van der Zee
R. Masereeuw - Co-supervisors
-
S.J.H. Vijverberg
- Award date
- 7 July 2021
- Number of pages
- 279
- ISBN
- 9789493184930
- Document type
- PhD thesis
- Faculty
- Faculty of Medicine (AMC-UvA)
- Abstract
-
Personalized cisplatin therapy could be of great potential to minimize the risk of side effects, especially nephrotoxicity without compromising its antineoplastic effect. It remains unclear if genetic factors can predict the risk of nephrotoxicity among cisplatin users. The primary objective of this thesis is to identify and validate genetic variants that could assist the prevention and management of cisplatin-induced nephrotoxicity through candidate gene studies and GWAS. The secondary objective is to identify strategies to minimize cisplatin-induced nephrotoxicity through modification of cisplatin dosing and optimization of co-medication selection. Part 1 of the thesis addresses the impact of genetic variations on cisplatin nephrotoxicity. The studies demonstrate that genetic predisposition could be important in the development of cisplatin-induced nephrotoxicity. These results warrant further replication effort, functional and pharmacokinetic/dynamic validation to reveal the mechanistic basis on how genetic variants may involve in cisplatin-induced nephrotoxicity. In the future, comprehensive assessment on cisplatin toxicities combined with an integration of cisplatin’s systems pharmacology and multi-omics cancer analysis could pave promising opportunities for individualized platinum selection and targeted organ protection including kidney. Part 2 explores the possibility of stratification and modification of cisplatin therapy to minimize nephrotoxicity without compromising its effectiveness. Modification of cisplatin dose and intensity, as well as optimization of standard co-medication such as 5-HT3 receptor antagonist antiemetics, could potentially minimize the risk of cisplatin-induced kidney injury without waiving its effectiveness. Further evidence from controlled trials and observational studies will strengthen the body of evidence to assess such potentially affordable prevention of cisplatin-induced nephrotoxicity.
- Persistent Identifier
- https://hdl.handle.net/11245.1/3eaee3ab-a2f6-49bf-a174-c7153ac71c11
- Downloads
-
Thesis (complete)
Front matter
Chapter 1: General introduction
Chapter 2: Genetic variations and cisplatin nephrotoxicity: A systematic review
Chapter 3: Organic cation transporters and nephrotoxicity: The impact of genetic polymorphisms
Chapter 4: Outcome definition influences the relationship between genetic polymorphisms of ERCC1, ERCC2, SLC22A2 and cisplatin nephrotoxicity in adult testicular cancer patients
Chapter 5: Association between genetic variants and cisplatin-induced nephrotoxicity: A genome-wide approach and validation study
Chapter 6: Cisplatin-induced nephrotoxicity in childhood cancer: Comparison between two countries
Chapter 7: Comparison of myelotoxicity and nephrotoxicity between daily low-dose cisplatin with concurrent radiation and cyclic high-dose cisplatin in non-small cell lung cancer patients
Chapter 8: Alleviation of cisplatin-induced nephrotoxicity by 5-HT₃ receptor antagonists
Chapter 9: General discussion
Summary; Samenvatting; List of publications; Acknowledgments; PhD portfolio; Curriculum vitae
- Supplementary materials
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.